News and Insights from Our Multidisciplinary Team of Experts
October 31, 2018 – Flagship Biosciences is honored to be named by Industry Era Magazine as one of the 10 Best Technology Solution Providers of 2018. The Industry Era Magazine article, Connecting Patients with Life-saving Drugs, notes Flagship’s ground-breaking...
October 30, 2018 – The true barrier for pathology AI is the business model, not the technology. To get pathology AI into the clinical laboratories, payers need to provide a value-based model that creates a viable business case. We estimate the U.S. anatomic pathology...
September 25, 2018 – Pathology AI Under a Central Lab Model: a cost-effective alternative and smart intermediate step for risk mitigation of a distributed medical device. A pathology AI system with an intended use for clinical diagnostics (Dx), prognostics (Px) or...
Hayward, CA and Westminster, CO – September 20, 2018 – Predicine and Flagship Biosciences are excited to announce a strategic venture. The synergistic combination of Predicine’s GeneRADAR molecular insights platform with Flagship’s artificial intelligence-enabled cTA®...
Frost & Sullivan News Release: Flagship Biosciences Recognized by Frost & Sullivan for Its Industry-leading AI-powered cTA® Platform for Predictive Diagnostics Santa Clara, CA, September 18, 2018 – Based on its recent analysis of the global market for...
September 10, 2018 – A pathology AI system with an intended use for clinical diagnostics (Dx), prognostics (Px) or companion diagnostics (CDx) can be commercialized as a medical device. Commercialization as a medical device requires: The pathology AI system to be...
Sign up to receive industry and company news, including The Cut Point, Flagship’s quarterly e-newsletter.
PUBLICATIONS/POSTERS
Key Concepts: While the current diagnostic strategies for PD-L1 checkpoint inhibitors identify some responders well, the majority of patients still need diagnostic approaches that better predict response. PD-L1 IHC remains a valuable tool for predicting patient...
Key takeaways Understanding the frequency and nature of immune cell clustering is useful in determining patient responses to immunomodulating therapies Flagship’s unique spatial biology services generated a validated computational pathology score that characterized...
Abstract Multiplexed analysis of limited tissue samples can improve our understanding of tumor biology and the tumor microenvironment. Chromogenic and fluorescent multiplexed immunohistochemistry (IHC) approaches are available and offer great insights while conserving...
EVENTS
Flagship presented three posters at the show, including: #AACR2021 poster no. 433: Clinical Validation of a Dickkopf-1 (DKK1) Chromogenic In-situ Hybridization (CISH) Assay for Manual and Image Analysis Assisted Pathologist Interpretation, in partnership with Leap...
SITC 2020 November 9-14, 2020As we prepare our poster presentation for the (virtual) Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting, we encourage you to register now (members register for FREE!)
Join Flagship Biosciences and our partners Gestalt Diagnostics for this informative webinar featuring an overview and discussion of the value of a truly integrated, digital pathology platform, using Artificial Intelligence (AI) to aid in diagnostic decisions! Flagship...